|
BR112013001553B1
(pt)
|
2010-07-22 |
2021-01-12 |
Gilead Sciences, Inc. |
compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem
|
|
MX2016014728A
(es)
*
|
2014-05-13 |
2017-03-23 |
Hoffmann La Roche |
Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
|
|
TWI698444B
(zh)
|
2014-10-29 |
2020-07-11 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
HK1244281B
(zh)
*
|
2015-02-11 |
2020-02-07 |
F. Hoffmann-La Roche Ag |
治疗和预防乙型肝炎病毒感染的2-氧代-6，7-二氢苯并[a]喹嗪-3-甲酸衍生物
|
|
CN107624113B
(zh)
|
2015-05-04 |
2020-10-23 |
豪夫迈·罗氏有限公司 |
作为HBsAg (HBV 表面抗原)和HBV DNA 生成的抑制剂用于治疗乙型肝炎病毒感染的四氢吡啶并嘧啶和四氢吡啶并吡啶类化合物
|
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2017016921A1
(en)
*
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
WO2017017042A1
(en)
|
2015-07-27 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
EP3328858B1
(en)
|
2015-07-28 |
2019-05-15 |
H. Hoffnabb-La Roche Ag |
Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
|
|
ES2918585T3
(es)
|
2015-09-16 |
2022-07-19 |
Gilead Sciences Inc |
Métodos para el tratamiento de infecciones por el virus Arenaviridae
|
|
SG11201806863WA
(en)
*
|
2016-02-19 |
2018-09-27 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
CN109069488B
(zh)
|
2016-03-07 |
2021-09-07 |
英安塔制药有限公司 |
乙型肝炎抗病毒剂
|
|
BR102017010009A2
(pt)
*
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
AU2017271990B2
(en)
|
2016-05-27 |
2019-12-19 |
Gilead Sciences, Inc. |
Methods for treating Hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
|
|
SG11201810834WA
(en)
|
2016-06-10 |
2018-12-28 |
Enanta Pharm Inc |
Hepatitis b antiviral agents
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
MA45496A
(fr)
*
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
JP7034133B2
(ja)
*
|
2016-07-14 |
2022-03-11 |
エフ．ホフマン－ラ ロシュ アーゲー |
感染性疾患の処置のためのカルボキシ ６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物
|
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
|
EP3490987B1
(en)
*
|
2016-07-29 |
2022-09-21 |
Guangzhou Lupeng Pharmaceutical Company Ltd. |
Novel therapeutic agents for the treatment of hbv infection
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018041873A1
(en)
*
|
2016-09-01 |
2018-03-08 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
PT3507276T
(pt)
|
2016-09-02 |
2022-01-11 |
Gilead Sciences Inc |
Compostos moduladores do recetor de tipo toll
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
US10662416B2
(en)
|
2016-10-14 |
2020-05-26 |
Precision Biosciences, Inc. |
Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
|
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
|
WO2018083136A1
(en)
|
2016-11-03 |
2018-05-11 |
F. Hoffmann-La Roche Ag |
Novel tetrahydroisoquinolines and terahydronaphthyridines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2018083106A1
(en)
|
2016-11-03 |
2018-05-11 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
EP3535261B1
(en)
|
2016-11-03 |
2020-08-05 |
F. Hoffmann-La Roche AG |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
SG11201902944TA
(en)
*
|
2016-11-07 |
2019-05-30 |
Arbutus Biopharma Corp |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
|
CN106810548B
(zh)
*
|
2017-01-13 |
2019-02-15 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
TW202510891A
(zh)
|
2017-01-31 |
2025-03-16 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
WO2018153285A1
(zh)
*
|
2017-02-23 |
2018-08-30 |
福建广生堂药业股份有限公司 |
三并环类化合物及其应用
|
|
CN110869028B
(zh)
|
2017-03-14 |
2023-01-20 |
吉利德科学公司 |
治疗猫冠状病毒感染的方法
|
|
CA3056886A1
(en)
|
2017-03-21 |
2018-09-27 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
AU2018262501B2
(en)
|
2017-05-01 |
2020-12-10 |
Gilead Sciences, Inc. |
Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
CN108530449B
(zh)
*
|
2017-05-22 |
2021-05-07 |
河南春风医药科技有限公司 |
用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
|
|
CN110066278B
(zh)
*
|
2017-06-01 |
2021-06-08 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
CA3077489A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
|
EP3675637A4
(en)
|
2017-08-28 |
2021-05-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
SG10202111648YA
(en)
*
|
2017-10-05 |
2021-11-29 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
KR102431353B1
(ko)
|
2017-10-16 |
2022-08-10 |
에프. 호프만-라 로슈 아게 |
B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
|
|
EP3700527A4
(en)
|
2017-10-25 |
2021-03-10 |
Children's Medical Center Corporation |
PAPD5 INHIBITORS AND METHOD OF USING THEM
|
|
EP3710455A1
(en)
|
2017-11-17 |
2020-09-23 |
Novartis AG |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
US10723733B2
(en)
|
2017-12-06 |
2020-07-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
TW201927789A
(zh)
|
2017-12-06 |
2019-07-16 |
美商因那塔製藥公司 |
B型肝炎抗病毒試劑
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111566120B
(zh)
|
2017-12-20 |
2023-09-29 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
|
|
CN111433210A
(zh)
*
|
2017-12-20 |
2020-07-17 |
诺华股份有限公司 |
作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
|
|
MX2020006596A
(es)
*
|
2017-12-22 |
2020-09-10 |
Bayer Ag |
Hidroxiisoxazolinas y derivados de estos.
|
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
|
WO2019143902A2
(en)
|
2018-01-22 |
2019-07-25 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
CR20200347A
(es)
|
2018-02-13 |
2020-09-23 |
Gilead Sciences Inc |
Inhibidores pd-1/pd-l1
|
|
US10836769B2
(en)
|
2018-02-26 |
2020-11-17 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds and uses thereof
|
|
WO2019166951A1
(en)
|
2018-02-28 |
2019-09-06 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
US11702427B2
(en)
|
2018-03-12 |
2023-07-18 |
Arbutus Biopharma Corporation |
Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
|
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
US11505551B2
(en)
|
2018-04-12 |
2022-11-22 |
Arbutus Biopharma Corporation |
Methods for preparing substituted pyridinone-containing tricyclic compounds
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
BR112020026973A2
(pt)
|
2018-07-03 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modulação da expressão tau
|
|
PT3820572T
(pt)
|
2018-07-13 |
2023-11-10 |
Gilead Sciences Inc |
Inibidores pd-1/pd-l1
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
CN110862390B
(zh)
|
2018-08-28 |
2023-05-09 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
MX2021003253A
(es)
|
2018-09-21 |
2021-08-11 |
Enanta Pharm Inc |
Heterociclos funcionalizados como agentes antivirales.
|
|
US11447498B2
(en)
|
2018-09-30 |
2022-09-20 |
Sunshine Lake Pharma Co., Ltd. |
Fused tetracyclic compounds and uses thereof in medicine
|
|
JP7158577B2
(ja)
|
2018-10-24 |
2022-10-21 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
EP4371987B9
(en)
|
2018-10-31 |
2025-11-26 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
KR102658602B1
(ko)
|
2018-10-31 |
2024-04-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
|
|
SG11202105007TA
(en)
|
2018-11-21 |
2021-06-29 |
Enanta Pharm Inc |
Functionalized heterocycles as antiviral agents
|
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN111410653B
(zh)
*
|
2019-01-08 |
2021-12-17 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
CN113543851B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
|
US20220143061A1
(en)
|
2019-03-07 |
2022-05-12 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
CN119798159A
(zh)
|
2019-04-24 |
2025-04-11 |
儿童医学中心公司 |
Papd5抑制剂及其使用方法
|
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
US11236111B2
(en)
|
2019-06-03 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US11760755B2
(en)
|
2019-06-04 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
WO2021007488A1
(en)
|
2019-07-11 |
2021-01-14 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
CA3149557A1
(en)
|
2019-09-30 |
2021-04-08 |
Scott J. Balsitis |
Hbv vaccines and methods treating hbv
|
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
HRP20241518T1
(hr)
|
2019-12-24 |
2025-01-03 |
Carna Biosciences, Inc. |
Spojevi koji moduliraju diacilglicerinkinazu
|
|
JP2023512656A
(ja)
|
2020-01-27 |
2023-03-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
|
|
AU2021234308C1
(en)
|
2020-03-12 |
2024-02-22 |
Gilead Sciences, Inc. |
Methods of preparing 1'-cyano nucleosides
|
|
WO2021188414A1
(en)
|
2020-03-16 |
2021-09-23 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
AR121620A1
(es)
|
2020-03-20 |
2022-06-22 |
Gilead Sciences Inc |
Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos
|
|
JP7482250B2
(ja)
|
2020-04-06 |
2024-05-13 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノ置換カルバヌクレオシド類似体の吸入製剤
|
|
CN115515596A
(zh)
*
|
2020-05-15 |
2022-12-23 |
福建广生中霖生物科技有限公司 |
包含三并环类化合物的组合及其在制备治疗hbv药物中的应用
|
|
PL4157272T3
(pl)
|
2020-05-29 |
2025-10-20 |
Gilead Sciences, Inc. |
Remdesiwir do leczenia zakażeń wirusowych
|
|
TWI819321B
(zh)
|
2020-06-24 |
2023-10-21 |
美商基利科學股份有限公司 |
1'-氰基核苷類似物及其用途
|
|
ES3054072T3
(en)
|
2020-08-07 |
2026-01-29 |
Gilead Sciences Inc |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
CN111943946B
(zh)
*
|
2020-08-19 |
2022-07-01 |
中国医学科学院医药生物技术研究所 |
含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用
|
|
WO2022046631A1
(en)
|
2020-08-24 |
2022-03-03 |
Gilead Sciences, Inc. |
Phospholipid compounds and uses thereof
|
|
WO2022047065A2
(en)
|
2020-08-27 |
2022-03-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
JP2024518558A
(ja)
|
2021-05-13 |
2024-05-01 |
ギリアード サイエンシーズ， インコーポレイテッド |
ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ
|
|
WO2022251318A1
(en)
|
2021-05-26 |
2022-12-01 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11976072B2
(en)
|
2021-06-23 |
2024-05-07 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
JP7719954B2
(ja)
|
2021-08-18 |
2025-08-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
リン脂質化合物並びにその製造方法及び使用方法
|
|
TWI867455B
(zh)
|
2022-03-02 |
2024-12-21 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
|
TW202525811A
(zh)
|
2022-03-02 |
2025-07-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
|
EP4486455A1
(en)
|
2022-03-03 |
2025-01-08 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
IL315082A
(en)
|
2022-03-03 |
2024-10-01 |
Gilead Sciences Inc |
Antiviral compounds and methods for its production and use
|
|
JP2025519390A
(ja)
|
2022-06-06 |
2025-06-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２を含むウイルス感染の治療方法
|
|
US20240051962A1
(en)
|
2022-06-29 |
2024-02-15 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
EP4547665A1
(en)
|
2022-06-30 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
WO2024173458A1
(en)
|
2023-02-16 |
2024-08-22 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
US20250090537A1
(en)
|
2023-08-31 |
2025-03-20 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
US20250084088A1
(en)
|
2023-08-31 |
2025-03-13 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
US20250099476A1
(en)
|
2023-09-06 |
2025-03-27 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US20250109157A1
(en)
|
2023-09-28 |
2025-04-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|